Company intelligence / Profile preview

Newleos Therapeutics

Boston, Massachusetts, United Statesthepharmaletter.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Lead program NTX-1955 has completed Phase 1 trials including single and multiple ascending dose studies, drug-drug interaction, and receptor occupancy studies, demonstrating it is safe, well tolerated, brain penetrant, and selective to GABAA-γ1. The company plans to investigate NTX-1955 in proof-of-concept clinical studies for generalized anxiety disorder in 2025.

Therapeutic areas: PsychiatryNeurology
Modalities: Oral small molecules
Industry: Biotech

Drug pipeline

1 asset

RO7308480

Unknown

Partnerships

Roche (licensed assets from)

Beyond the preview

Go deeper on Newleos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Newleos Therapeutics.

Explore the full profile